BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia

Reuters

19 Feb

BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia

Feb 19 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:

HARMONY BIOSCIENCES PROVIDES UPDATE ON THE STATUS OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR PITOLISANT IN IDIOPATHIC HYPERSOMNIA
HARMONY BIOSCIENCES HOLDINGS INC - 2025 NET REVENUE GUIDANCE REMAINS UNCHANGED AT $820-$860 MILLION
HARMONY BIOSCIENCES HOLDINGS INC - TO INITIATE PHASE 3 TRIAL OF PITOLISANT HD IN Q4 2025
HARMONY BIOSCIENCES HOLDINGS INC - RECEIVES FDA REFUSAL TO FILE LETTER FOR PITOLISANT
HARMONY BIOSCIENCES -ON TRACK TO INITIATE A PHASE 3 REGISTRATIONAL TRIAL OF PITOLISANT HD IN IH IN Q4 2025, WITH A TARGET PDUFA DATE IN 2028

Source text: ID:nBw4VR77Na

Further company coverage: HRMY.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2512585486"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512585486\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2512585486?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-19 23:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512585486","market":"us","top_or_hot":-1,"title":"BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia</title></head><body><p><span>Feb 19 (Reuters)</span><span> - </span>Harmony Biosciences Holdings Inc <span>HRMY.O</span>:</p><ul><li><p>HARMONY BIOSCIENCES PROVIDES UPDATE ON THE STATUS OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR PITOLISANT IN IDIOPATHIC HYPERSOMNIA</p></li><li><p>HARMONY BIOSCIENCES HOLDINGS INC - 2025 NET REVENUE GUIDANCE REMAINS UNCHANGED AT $820-$860 MILLION</p></li><li><p>HARMONY BIOSCIENCES HOLDINGS INC - TO INITIATE PHASE 3 TRIAL OF PITOLISANT HD IN Q4 2025</p></li><li><p>HARMONY BIOSCIENCES HOLDINGS INC - RECEIVES FDA REFUSAL TO FILE LETTER FOR PITOLISANT</p></li><li><p>HARMONY BIOSCIENCES -ON TRACK TO INITIATE A PHASE 3 REGISTRATIONAL TRIAL OF PITOLISANT HD IN IH IN Q4 2025, WITH A TARGET PDUFA DATE IN 2028</p></li></ul><p>Source text: <span>ID:nBw4VR77Na</span></p><p>Further company coverage: <span>HRMY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-19 23:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia</title></head><body><p><span>Feb 19 (Reuters)</span><span> - </span>Harmony Biosciences Holdings Inc <span>HRMY.O</span>:</p><ul><li><p>HARMONY BIOSCIENCES PROVIDES UPDATE ON THE STATUS OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR PITOLISANT IN IDIOPATHIC HYPERSOMNIA</p></li><li><p>HARMONY BIOSCIENCES HOLDINGS INC - 2025 NET REVENUE GUIDANCE REMAINS UNCHANGED AT $820-$860 MILLION</p></li><li><p>HARMONY BIOSCIENCES HOLDINGS INC - TO INITIATE PHASE 3 TRIAL OF PITOLISANT HD IN Q4 2025</p></li><li><p>HARMONY BIOSCIENCES HOLDINGS INC - RECEIVES FDA REFUSAL TO FILE LETTER FOR PITOLISANT</p></li><li><p>HARMONY BIOSCIENCES -ON TRACK TO INITIATE A PHASE 3 REGISTRATIONAL TRIAL OF PITOLISANT HD IN IH IN Q4 2025, WITH A TARGET PDUFA DATE IN 2028</p></li></ul><p>Source text: <span>ID:nBw4VR77Na</span></p><p>Further company coverage: <span>HRMY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA35RXXV:1","article_id":"2512585486","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512585486","pubTimestamp":1739978563,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic HypersomniaFeb 19 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:HARM","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HRMY":"Harmony Biosciences Holdings, Inc."},"translate_title":"BRIEF-Harmony Biosciences提供垂体后叶素治疗特发性嗜睡症补充新药申请的最新状态","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":0.9},"content_text":"BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic HypersomniaFeb 19 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:HARMONY BIOSCIENCES PROVIDES UPDATE ON THE STATUS OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR PITOLISANT IN IDIOPATHIC HYPERSOMNIAHARMONY BIOSCIENCES HOLDINGS INC - 2025 NET REVENUE GUIDANCE REMAINS UNCHANGED AT $820-$860 MILLIONHARMONY BIOSCIENCES HOLDINGS INC - TO INITIATE PHASE 3 TRIAL OF PITOLISANT HD IN Q4 2025HARMONY BIOSCIENCES HOLDINGS INC - RECEIVES FDA REFUSAL TO FILE LETTER FOR PITOLISANTHARMONY BIOSCIENCES -ON TRACK TO INITIATE A PHASE 3 REGISTRATIONAL TRIAL OF PITOLISANT HD IN IH IN Q4 2025, WITH A TARGET PDUFA DATE IN 2028Source text: ID:nBw4VR77NaFurther company coverage: HRMY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}